Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Sept. 20, 2024
Language: Английский
Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(4), P. 1143 - 1143
Published: April 4, 2023
Cancer immunotherapy is a type of treatment that harnesses the power immune systems patients to target cancer cells with better precision compared traditional chemotherapy. Several lines have been approved by US Food and Drug Administration (FDA) led remarkable success in solid tumors, such as melanoma small-cell lung cancer. These immunotherapies include checkpoint inhibitors, cytokines, vaccines, while chimeric antigen receptor (CAR) T-cell has shown responses hematological malignancies. Despite these breakthrough achievements, response variable among patients, only small percentage gained from this treatment, depending on histological tumor other host factors. develop mechanisms avoid interacting circumstances, which an adverse effect how effectively they react therapy. arise either due intrinsic factors within or microenvironment (TME). When scenario used therapeutic setting, term “resistance immunotherapy” applied; “primary resistance” denotes failure respond start, “secondary relapse following initial immunotherapy. Here, we provide thorough summary internal external underlying resistance Furthermore, variety are briefly discussed, along recent developments employed prevent relapses focus upcoming initiatives improve efficacy for patients.
Language: Английский
Citations
52
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: April 29, 2024
Abstract Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made great progress in the systemic treatment of HCC. The combination treatments based on ICIs been trend this area. Recently, dual blockade durvalumab plus tremelimumab has also emerged an effective for advanced However, majority HCC patients obtain benefits. Understanding immunological rationale exploring novel ways to improve efficacy immunotherapy drawn much attention. review, we summarize latest area, ongoing clinical trials immune-based therapies, well strategies chimeric antigen receptor T cells, personalized neoantigen vaccines, oncolytic viruses, bispecific antibodies.
Language: Английский
Citations
41
Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)
Published: March 22, 2024
Abstract Inflammation has accompanied human beings since the emergence of wounds and infections. In past decades, numerous efforts have been undertaken to explore potential role inflammation in cancer, from tumor development, invasion, metastasis resistance tumors treatment. Inflammation-targeted agents not only demonstrate suppress cancer but also improve efficacy other therapeutic modalities. this review, we describe highly dynamic complex inflammatory microenvironment, with discussion on key mediators including cells, cytokines, their downstream intracellular pathways. addition, especially address development highlight action mechanisms inflammation-targeted therapies antitumor response. Finally, summarize results both preclinical clinical studies up date illustrate translation therapies.
Language: Английский
Citations
32
Advanced Materials, Journal Year: 2024, Volume and Issue: 36(19)
Published: Feb. 7, 2024
Neutrophils are the most abundant white blood cells in circulation and act as first line of defense against infections. Increasing evidence suggests that neutrophils possess heterogeneous phenotypes functional plasticity human health diseases, including cancer. play multifaceted roles cancer development progression, an N1/N2 paradigm is proposed, where N1 exert anti-tumor properties while N2 display tumor-supportive immune-suppressive functions. Selective activation beneficial neutrophil population targeted inhibition or re-polarization tumor-promoting has shown important potential tumor therapy. In addition, due to natural inflammation-responsive physical barrier-crossing abilities, their derivatives (membranes extracellular vesicles (EVs)) regarded advanced drug delivery carriers for enhanced targeting improved therapeutic efficacy. this review, recent advances engineering remodeling microenvironment (TME) comprehensively presented. This review will provide a broad understanding
Language: Английский
Citations
30
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Sept. 20, 2024
Language: Английский
Citations
29